CD274 and non-small cell lung carcinoma: Unlike non-small-cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC), where PD-L1 expression thresholds (1–50%) have been validated for pembrolizumab, no established ATC-specific cutoff values currently exist [67].